Strategic Partnerships Aviceda Therapeutics combines glyco-immuno therapeutics with proprietary HALOS nanoparticle technology to address ocular and systemic inflammatory diseases. This creates opportunities for BD teams to explore collaborations with ophthalmology-focused pharma, contract research organizations, and academic centers specializing in retinal diseases, fibrosis, and immune-mediated conditions.

Clinical-stage Opportunity As a clinical-stage biotech with a Phase 2/3 trial for AVD-104 in geographic atrophy, Aviceda presents a near-term entry point for co-development, licensing, or strategic funding discussions, particularly with investors and pharma seeking late-stage orphan/limited-competition indications.

High Affinity Ligands HALOS platform emphasizes high-affinity ligands of Siglecs and customizable nanoparticle conjugation, suggesting potential for collaboration in biomarker-guided trials, companion diagnostics, or targeted immunomodulatory therapies aligned with companies focusing on innate immunity and inflammatory modulation.

Expansion Financing Recent financing activity including multi-hundred-million rounds signals strong investor enthusiasm and capital availability for partnerships or equity-backed collaboration deals, particularly with funders specialized in biotech, ophthalmology, or immuno-inflammatory franchises.

Global Research Network Existing collaborations with Queen’s University Belfast and a CET-like HTS capability position Aviceda as a gateway for academic-industry partnerships, joint research programs, and regional market entry strategies in Europe and beyond through co-development or sponsored research agreements.